Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report) was down 2.4% on Thursday . The company traded as low as $48.21 and last traded at $48.89. Approximately 264,595 shares changed hands during trading, an increase of 40% from the average daily volume of 189,291 shares. The stock had previously closed at $50.08.
Gemini Therapeutics Trading Down 3.1%
The company has a market capitalization of $1.99 billion, a PE ratio of -45.88 and a beta of -0.12. The company has a fifty day simple moving average of $45.48 and a 200-day simple moving average of $54.51.
About Gemini Therapeutics
(
Get Free Report)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
Before you consider Gemini Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gemini Therapeutics wasn't on the list.
While Gemini Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
